ST Germain D J Co. Inc. Cuts Position in CVS Health Co. (NYSE:CVS)

ST Germain D J Co. Inc. cut its holdings in CVS Health Co. (NYSE:CVS) by 15.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 248,613 shares of the pharmacy operator’s stock after selling 44,669 shares during the period. ST Germain D J Co. Inc.’s holdings in CVS Health were worth $11,160,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sound Income Strategies LLC grew its stake in CVS Health by 7.2% in the third quarter. Sound Income Strategies LLC now owns 2,397 shares of the pharmacy operator’s stock worth $151,000 after purchasing an additional 162 shares in the last quarter. Hexagon Capital Partners LLC increased its stake in CVS Health by 3.5% in the 3rd quarter. Hexagon Capital Partners LLC now owns 5,268 shares of the pharmacy operator’s stock worth $331,000 after purchasing an additional 178 shares in the last quarter. Bruce G. Allen Investments LLC lifted its stake in CVS Health by 13.1% in the 3rd quarter. Bruce G. Allen Investments LLC now owns 1,681 shares of the pharmacy operator’s stock worth $106,000 after acquiring an additional 195 shares in the last quarter. HHM Wealth Advisors LLC boosted its stake in shares of CVS Health by 11.9% during the 2nd quarter. HHM Wealth Advisors LLC now owns 1,886 shares of the pharmacy operator’s stock valued at $111,000 after buying an additional 200 shares during the period. Finally, Integrated Advisors Network LLC raised its position in CVS Health by 0.7% during the third quarter. Integrated Advisors Network LLC now owns 27,625 shares of the pharmacy operator’s stock valued at $1,737,000 after acquiring an additional 200 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Up 3.8 %

Shares of CVS stock traded up $1.74 on Friday, hitting $47.75. The stock had a trading volume of 5,675,796 shares, compared to its average volume of 11,498,649. The company has a fifty day moving average price of $51.98 and a two-hundred day moving average price of $56.68. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. The firm has a market cap of $60.09 billion, a P/E ratio of 12.12, a PEG ratio of 0.85 and a beta of 0.59. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The company had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. During the same quarter in the prior year, the company earned $2.21 earnings per share. The business’s quarterly revenue was up 6.3% compared to the same quarter last year. As a group, analysts forecast that CVS Health Co. will post 5.32 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd will be issued a $0.665 dividend. The ex-dividend date is Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 5.57%. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Analysts Set New Price Targets

Several research analysts have commented on CVS shares. Barclays dropped their price target on CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th. Cantor Fitzgerald reissued a “neutral” rating and issued a $62.00 target price on shares of CVS Health in a research note on Tuesday, October 1st. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, December 3rd. UBS Group upped their price target on CVS Health from $60.00 to $62.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Finally, Royal Bank of Canada reduced their target price on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $68.71.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.